Summit TherapeuticsSMMT
SMMT
About: Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Employees: 159
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
164% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 25
97% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 38
22% more funds holding
Funds holding: 166 [Q3] → 202 (+36) [Q4]
0.89% more ownership
Funds ownership: 11.66% [Q3] → 12.55% (+0.89%) [Q4]
11% less capital invested
Capital invested by funds: $1.85B [Q3] → $1.65B (-$196M) [Q4]
32% less call options, than puts
Call options by funds: $36.7M | Put options by funds: $53.9M
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
24%
upside
Avg. target
$38
58%
upside
High target
$44
82%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Reni Benjamin 20% 1-year accuracy 8 / 40 met price target | 66%upside $40 | Market Outperform Reiterated | 28 Apr 2025 |
Jefferies Kelly Shi 27% 1-year accuracy 3 / 11 met price target | 82%upside $44 | Buy Maintained | 25 Apr 2025 |
Citigroup Yigal Nochomovitz 20% 1-year accuracy 8 / 41 met price target | 45%upside $35 | Buy Upgraded | 26 Mar 2025 |
Evercore ISI Group Cory Kasimov 47% 1-year accuracy 8 / 17 met price target | 24%upside $30 | Outperform Initiated | 12 Mar 2025 |
Goldman Sachs Salveen Richter 20% 1-year accuracy 4 / 20 met price target | 74%upside $42 | Buy Initiated | 28 Feb 2025 |
Financial journalist opinion
Based on 15 articles about SMMT published over the past 30 days
Positive
Benzinga
2 days ago
Why Is Summit Therapeutics Stock Trading Higher On Monday?
Summit Therapeutics Inc. SMMT on Friday noted that Akeso, Inc. announced the Chinese Health Authorities, the National Medical Products Administration (NMPA) approved ivonescimab for a second indication based on the results of the Phase 3 trial, HARMONi-2 or AK112-303.
Negative
The Motley Fool
5 days ago
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today
Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the place on Friday. Both U.S.-based Summit Therapeutics (SMMT -36.19%) and BioNTech (BNTX -15.40%) were down significantly, plunging 36.1% and 15.4%, respectively, in Friday's trading.
Negative
Benzinga
5 days ago
What's Going On With Summit Therapeutics Stock On Friday?
Summit Therapeutics Inc SMMT stock is trading lower on Friday.
Neutral
Business Wire
5 days ago
Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that ivonescimab was approved by the Chinese Health Authorities, the National Medical Products Administration (NMPA), for a second indication based on the results of the Phase III clinical trial, HARMONi-2 or AK112-303. HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced o.
Neutral
Business Wire
6 days ago
Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its first quarter 2025 financial results and provide an operational update for the Company on Thursday, May 1, 2025, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. About Summ.
Positive
The Motley Fool
1 week ago
Why Summit Therapeutics Rocketed Double-Digits Today
Shares of lung cancer biotech Summit Therapeutics (SMMT 21.72%) rocketed 14.7% on Wednesday as of 1:45 p.m. ET.
Positive
Benzinga
1 week ago
Why Is Summit Therapeutics Stock Soaring On Wednesday?
Summit Therapeutics Inc.'s SMMT partner, Akeso, Inc., released topline data from the Phase 3 HARMONi-6/K112-306 trial on Wednesday.
Neutral
Business Wire
1 week ago
Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that the Phase III clinical trial, HARMONi-6 or AK112-306, met its primary endpoint of progression-free survival (PFS). HARMONi-6 is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, a PD-1 inhibitor, in combination with platinum-based chemotherapy in patients with locally advanced o.
Positive
The Motley Fool
1 week ago
This Company's Co-CEOs Just Bought More Shares. Should You?
Nobody has more information about a company than its insiders, especially its executive management team. That's why when one of them buys more shares, it sometimes gives individual investors insights into the company's prospects.
Neutral
Seeking Alpha
2 weeks ago
Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition
Summit Therapeutics' ivonescimab shows promising results in China, outperforming Keytruda in PD-L1 positive advanced NSCLC, with potential $10 billion peak annual revenue. Fierce competition exists in the PD-1/VEGF bispecific antibody space, with major players like Merck and BioNTech entering the market. Summit's financial health shows a significant cash runway into late 2027, despite high R&D and G&A expenses and no revenue generation.
Charts implemented using Lightweight Charts™